Document Classification

Section Type: METHODS

Text: Healthy infants randomized in a previous study for priming at 2, 4, and 6 months : Hib-MenC-TT primed group, 3 doses of Hib-MenC-TT + DTPa-HBV-IPV (N = 87) ; MenC-TT primed group, 2 doses of MenC-TT (NeisVac-C ; Baxter Healthcare SA, Zurich, Switzerland) + 3 doses of DTPa/Hib containing vaccines (N = 178) ; MenC-CRM primed group, 3 doses of MenC-CRM197 (Meningitec ; Wyeth Corporation Delaware, Madison, NJ) + DTPa-HBV-IPV/Hib (N = 93).